Company intelligence / Profile preview

Nika BioTechnology

Henderson, Colorado, United States

Ownership: Private
Development stage: Other

Overview

The company claims successful Phase 3 clinical results for Thymus Nuclear Glycoprotein (TNG) in advanced HIV/AIDS patients and offers several dietary supplements with metabolic and immune-boosting effects. Other injectable products (drugs) are in various stages, with at least two programs reporting positive clinical trial results.

Therapeutic areas: ImmunologyInfectious DiseasesEndocrinologyOncology
Modalities: Small moleculeBiologicDietary supplementRecombinant protein
Industry: Biotech

Partnerships

VITAL FE Joint Stock Company (TNG production/distribution)MICAR 11 Ltd. (Carotilen, Physiolong distribution)Dimitar Slavchev Savov (distribution of 6 dietary supplements)Immunotech Laboratories BG

Beyond the preview

Go deeper on Nika BioTechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nika BioTechnology.

Explore the full profile